Study on Transplanting Organs from Hepatitis C Positive Patients

Introduction to the Organ Transplant Crisis

A recent study explored the safety and efficacy of transplanting organs from hepatitis C positive (HCV+) donors into hepatitis C negative (HCV-) transplant recipients, accompanied by antiviral therapy. Each year, numerous patients awaiting heart transplants either succumb to their conditions or become too ill to undergo the procedure. The scarcity of organ donors exacerbates this situation, particularly in light of the recent opioid crisis, which has led to an increase in potential organ donors contracting HCV, resulting in the need to discard these organs.

Advancements in Hepatitis C Treatment

Historically, treatments for HCV were linked to poor outcomes and significant side effects. However, recent advancements in direct-acting antiviral (DAA) therapies have shown remarkable efficacy in curing HCV with minimal to no adverse effects. This progress has prompted researchers to consider the transplantation of HCV-infected organs into HCV-negative recipients, followed by DAA treatment, as a viable option to increase the availability of usable organs.

Previous Research Findings

Five independent studies have reported a 100% cure rate for HCV-positive organ transplants following DAA treatment. Despite this encouraging data, only one of the studies focused on heart transplants, indicating a need for further research to assess the safety of transplanting HCV-positive hearts into HCV-negative patients.

Current Study Overview

To address this gap, McLean and colleagues conducted a study involving ten HCV-negative patients in need of heart transplants. Each participant received a heart from an HCV-positive donor and subsequently underwent twelve weeks of DAA therapy, specifically elbasvir/grazoprevir. The researchers monitored HCV levels and any adverse events throughout the study, with results published in the American Journal of Transplantation.

Study Results

Initially, all ten participants exhibited detectable levels of HCV three days post-transplantation. By the conclusion of the treatment regimen, nine out of ten participants reported no adverse effects and successfully achieved a cure for their HCV. One patient, unfortunately, passed away on day 79 due to antibody-mediated rejection, a circumstance the authors clarified was unrelated to the HCV-positive organ transplantation or DAA therapy.

Conclusion and Future Research Directions

The researchers concluded that HCV-negative patients who received HCV-positive organs did not experience adverse outcomes and were cured of the contracted HCV through DAA treatment. Ongoing studies aim to explore whether similar transplantation approaches can be applied to other organs infected with HCV, such as lungs and kidneys. Additionally, further long-term and larger-scale trials are essential to validate the effectiveness of HCV-positive organ transplants following antiviral therapy.

Reference

McLean, R. C., Reese, P. P., Acker, M., Atluri, P., Bermudez, C., Goldberg, L., … & Bloom, R. D. (2019). Transplanting hepatitis C virus‐infected hearts into uninfected recipients: A single‐arm trial. American Journal of Transplantation.